Diabetic nephropathy

Correlation between polymorphisms of hypoxia-inducible factor-1α Pro582Ser and type 2 diabetic nephropathy

Y. X. Bi, Yu, L., and Jin, G. X., Correlation between polymorphisms of hypoxia-inducible factor-1α Pro582Ser and type 2 diabetic nephropathy, vol. 14, pp. 14503-14509, 2015.

We examined the correlation between gene polymorphisms in hypoxia-inducible factor-1α (HIF-1α) Pro582Ser and type 2 diabetic nephropathy (DN). A total of 244 subjects with type 2 diabetes were recruited. The 1285-bp locus polymorphism of HIF-1α exon was detected using polymerase chain reaction-restriction fragment length polymorphism. C/T single nucleotide polymorphisms were detected at the site of 1285 bp of the HIF-1α exon, from a proline to a serine (Pro582Ser). The frequency of CT heterozygotes was significantly higher in DN patients than in diabetes patients (P < 0.05).

Correlation between serum YKL-40 levels and albuminuria in type 2 diabetes

J. Y. Han, Ma, X. Y., Yu, L. J., Shao, Y., and Wang, Q. Y., Correlation between serum YKL-40 levels and albuminuria in type 2 diabetes, vol. 14, pp. 18596-18603, 2015.

We explored the correlation between serum YKL-40 levels and albuminuria in type 2 diabetes mellitus (T2DM) and its clinical significance. This study used a cross-sectional survey method. According to the American Diabetes Association 2007 Clinical Practice Recommendations, 738 patients with T2DM were divided into three groups: a normoalbuminuria group [albumin-to-creatinine ratio (ACR) vs the control group (P vs the microalbuminuria group (P vs the normoalbuminuria group (P

Associations between INSR and MTOR polymorphisms in type 2 diabetes mellitus and diabetic nephropathy in a Northeast Chinese Han population

A. N. Zhu, Yang, X. X., Sun, M. Y., Zhang, Z. X., and Li, M., Associations between INSR and MTOR polymorphisms in type 2 diabetes mellitus and diabetic nephropathy in a Northeast Chinese Han population, vol. 14, pp. 1808-1818, 2015.

We explored the associations of INSR and mTOR, 2 key genes in the insulin signaling pathway, and the susceptibility to type 2 diabetes mellitus and diabetic nephropathy. Three single-nucleotide polymorphisms (SNPs) (rs1799817, rs1051690, and rs2059806) in INSR and 3 SNPs (rs7211818, rs7212142, and rs9674559) in mTOR were genotyped using the Sequenom MassARRAY iPLEX platform in 89 type 2 diabetes patients without diabetic nephropathy, 134 type 2 diabetes patients with diabetic nephropathy, and 120 healthy control subjects.

Effects of Astragaloside IV on diabetic nephropathy in rats

W. - S. Lu, Li, S., Guo, W. - W., Chen, L. - L., and Li, Y. - S., Effects of Astragaloside IV on diabetic nephropathy in rats, vol. 14, pp. 5427-5434, 2015.

The aims of this study were to explore the effects of Astragaloside IV on diabetic nephropathy (DN) rats. A total of 38 male Sprague-Dawley (SD) rats were divided into three groups: 10 in the normal (control) group, 14 in the DN model group, and 14 in the AS-IV group. Treatment began one week after the streptozotocin DN model was successfully established. Blood glucose and urine micro-albumin levels were measured every four weeks. After being treated for 12 weeks, all SD rats were sacrificed for blood and renal specimen collec­tion.

Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy

J. Guan, Long, L., Chen, Y. - Q., Yin, Y., Li, L., Zhang, C. - X., Deng, L., and Tian, L. - H., Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy, vol. 13, pp. 4154-4158, 2014.

Beraprost sodium (BPS) is a prostaglandin analogue. We investigated its effects on rats with diabetic nephropathy. There were 20 rats each in the normal control group (NC), the diabetic nephropathy group (DN), and the BPS treatment group. The rats in DN and BPS groups were given a high-fat diet combined with low-dose streptozotocin intraperitoneal injections. The rats in the BPS group were given daily 0.6 mg/kg intraperitoneal injections of this drug.

Rituximab regulates the expression of the Raf kinase inhibitor protein via NF-κB in renal tissue of rats with diabetic nephropathy

L. Li, Zhao, Y. W., Zeng, J. S., Fan, F., Wang, X., Zhou, Y., and Zhu, Z., Rituximab regulates the expression of the Raf kinase inhibitor protein via NF-κB in renal tissue of rats with diabetic nephropathy, vol. 12, pp. 2973-2981, 2013.

This study aimed to investigate the expression levels of the Raf kinase inhibitor protein (RKIP) and NF-κB in renal tissues of diabetic nephropathy (DN) rats, and to determine the underlying molecular targets of rituximab (RTX), with the goal of developing new clinical treatment selection for DN. Sprague-Dawley rats were randomly divided into a normal group (N), a DN group (M), and an RTX treatment group (D). Blood glucose and 24-h urine protein levels of rats were determined.

Subscribe to Diabetic nephropathy